Difference between revisions of "Melphalan (Alkeran)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information")
 
(12 intermediate revisions by 2 users not shown)
Line 4: Line 4:
 
<br>Extravasation: [[irritant]] or [[neutral]], depending on reference
 
<br>Extravasation: [[irritant]] or [[neutral]], depending on reference
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref>  
 +
 
 +
==Diseases for which it is established ''(work in progress)''==
 +
*[[Peripheral T-cell lymphoma]]
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
Line 10: Line 13:
 
*[[Acute promyelocytic leukemia]]
 
*[[Acute promyelocytic leukemia]]
 
*[[Ewing sarcoma]]
 
*[[Ewing sarcoma]]
−
*[[Hodgkin lymphoma]]
+
*[[Classical Hodgkin lymphoma]]
 
*[[Neuroblastoma]]
 
*[[Neuroblastoma]]
 
*Non-Hodgkin lymphoma
 
*Non-Hodgkin lymphoma
Line 18: Line 21:
 
**[[HIV-associated lymphoma]]
 
**[[HIV-associated lymphoma]]
 
**[[Mantle cell lymphoma]]
 
**[[Mantle cell lymphoma]]
−
**[[Peripheral T-cell lymphoma]]
 
 
*Plasma cell dyscrasia
 
*Plasma cell dyscrasia
 
**[[Light-chain (AL) amyloidosis]]
 
**[[Light-chain (AL) amyloidosis]]
Line 29: Line 31:
  
 
==Patient drug information==
 
==Patient drug information==
−
*[https://chemocare.com/chemotherapy/drug-info/Melphalan.aspx Melphalan (Alkeran) patient drug information (Chemocare)]<ref>[https://chemocare.com/chemotherapy/drug-info/Melphalan.aspx Melphalan (Alkeran) patient drug information (Chemocare)]</ref>
+
*[https://chemocare.com/druginfo/Melphalan.aspx Melphalan (Alkeran) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/Melphalan.aspx Melphalan (Alkeran) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]</ref>
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
*1/17/1964: Initial FDA approval<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=014691&DrugName=ALKERAN&ActiveIngred=MELPHALAN&SponsorApplicant=GLAXOSMITHKLINE&ProductMktStatus=1&goto=Search.Label_ApprovalHistory Melphalan (Alkeran) FDA approval history]</ref>
+
*1964-01-17: Initial FDA approval<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=014691&DrugName=ALKERAN&ActiveIngred=MELPHALAN&SponsorApplicant=GLAXOSMITHKLINE&ProductMktStatus=1&goto=Search.Label_ApprovalHistory Melphalan (Alkeran) FDA approval history]</ref>
−
* Indicated for the palliative treatment of [[multiple myeloma]] and for the palliation of non-resectable [[Ovarian_cancer|epithelial carcinoma of the ovary]].
+
*Uncertain date: Indicated for the palliative treatment of [[multiple myeloma]]. ''(Based on SWG01)''
−
 
+
*Uncertain date: Indicated for the palliation of non-resectable [[Ovarian_cancer|epithelial carcinoma of the ovary]]. ''(No supporting studies are cited)''
 +
==History of changes in EMA indication==
 +
*1963-09-26: EURD
 
==Also known as==
 
==Also known as==
 
*'''Generic names:''' L-PAM, L-Sacrolysin, L-Sarcolysin, MPL, phenylalanine mustard
 
*'''Generic names:''' L-PAM, L-Sacrolysin, L-Sarcolysin, MPL, phenylalanine mustard
−
*'''Brand names:''' Alkeran, Alkerana, Evomela, Levofolan, Melfalan
+
*'''Brand names:''' Alkeran, Alkerana, Evomela, Levofolan, Melfalan, Phelinun
  
 
==References==
 
==References==
Line 60: Line 64:
 
[[Category:Follicular lymphoma medications]]
 
[[Category:Follicular lymphoma medications]]
 
[[Category:HIV-associated lymphoma medications]]
 
[[Category:HIV-associated lymphoma medications]]
−
[[Category:Hodgkin lymphoma medications]]
+
[[Category:Classical Hodgkin lymphoma medications]]
 
[[Category:Light-chain (AL) amyloidosis medications]]
 
[[Category:Light-chain (AL) amyloidosis medications]]
 
[[Category:Mantle cell lymphoma medications]]
 
[[Category:Mantle cell lymphoma medications]]
Line 72: Line 76:
  
 
[[Category:FDA approved in 1964]]
 
[[Category:FDA approved in 1964]]
 +
[[Category:EMA approved in 1963]]
 
[[Category:WHO Essential Cancer Medicine]]
 
[[Category:WHO Essential Cancer Medicine]]

Latest revision as of 01:04, 29 June 2024

General information

Class/mechanism: Nitrogen mustard, alkylator. Melphalan is a bischloroethylamine alkylating agent that crosslinks DNA by binding at the N7 position of guanine, with activity against resting and proliferating cells.[1][2]
Route: IV, PO
Extravasation: irritant or neutral, depending on reference

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

  • 1964-01-17: Initial FDA approval[5]
  • Uncertain date: Indicated for the palliative treatment of multiple myeloma. (Based on SWG01)
  • Uncertain date: Indicated for the palliation of non-resectable epithelial carcinoma of the ovary. (No supporting studies are cited)

History of changes in EMA indication

  • 1963-09-26: EURD

Also known as

  • Generic names: L-PAM, L-Sacrolysin, L-Sarcolysin, MPL, phenylalanine mustard
  • Brand names: Alkeran, Alkerana, Evomela, Levofolan, Melfalan, Phelinun

References

  1. ↑ 1.0 1.1 Melphalan (Alkeran) package insert
  2. ↑ Melphalan (Alkeran) package insert (locally hosted backup)
  3. ↑ Melphalan (Alkeran) patient drug information (Chemocare)
  4. ↑ Melphalan (Alkeran) patient drug information (UpToDate)
  5. ↑ Melphalan (Alkeran) FDA approval history
Retrieved from "https://hemonc.org/w/index.php?title=Melphalan_(Alkeran)&oldid=87341"